Heat Biologics, Inc. to Present and Webcast at Two Investor Conferences in September

- Rodman & Renshaw 16th Annual Global Investment Presentation on September 9, 2014 -

- Aegis Capital 2014 Healthcare and Technology Presentation on September 12, 2014 -

DURHAM, N.C., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference being held September 8 - 10, 2014 at the New York Palace Hotel in New York and the Aegis Capital Healthcare and Technology Conference being held September 10 - 13, 2014 at the Encore at Wynn in Las Vegas.

Event: Rodman & Renshaw 16th Annual Global Investment Conference
Date:  Tuesday, September 9, 2014
Time: 10:00 a.m. Eastern Time
Location: New York Palace Hotel, New York, NY
Event: Aegis Capital Healthcare and Technology Conference
Date: Friday, September 12, 2014
Time: 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time)
Location: Encore at Wynn, Las Vegas, NV

Live audio webcasts of both the Rodman & Renshaw presentation and the Aegis Capital presentation will be available on the Company's website (www.heatbio.com) on the Investor Relations Events page at http://ir.heatbio.com/events.  The webcast replays will be available approximately two hours after each presentation ends and will be accessible for one month.

About Heat Biologics, Inc. 

Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers.  Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells.  Heat's Viagenpumatucel-L (HS-110) will be entering Phase 2 trials against non-small cell lung cancer and its Vesigenurtacel-L (HS-410) is being evaluated in an ongoing Phase 1/2 clinical trial against bladder cancer.

CONTACT: Heat Biologics, Inc. Contact Information:
         Matthew Czajkowski
         Chief Financial Officer
         (919) 240-7133

         Jenene Thomas
         Investor Relations and Corporate Communications Advisor
         Jenene Thomas Communications, LLC
         (908) 938-1475

Heat Biologics

Source: Heat Biologics